Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 797 across all filing types
Latest filing 2023-08-14 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2023-08-14 English
Pharming Group to convene Extraordinary General Meeting of Shareholders
AGM Information Classification · 98% confidence The document is a press release announcing that Pharming Group N.V. is convening an Extraordinary General Meeting of Shareholders (Buitengewone Algemene Vergadering van Aandeelhouders - BAvA) on September 25, 2023. The key topics mentioned are the appointment of a new Non-Executive Director and an increase in the remuneration policy for the Chairman of the Board. This announcement directly relates to the logistics and agenda of a shareholder meeting, which falls under the scope of AGM Information (AGM-R). Although it announces the meeting, the content details the specific items to be voted on, making AGM-R more specific than a general Report Publication Announcement (RPA).
2023-08-14 Dutch
Pharming Group to convene Extraordinary General Meeting of Shareholders
AGM Information Classification · 98% confidence The document explicitly announces that Pharming Group N.V. will convene an 'Extraordinary General Meeting of Shareholders (EGM)' on a specific date. It details the agenda items, which include the appointment of a new director and changes to the Remuneration Policy. This content directly relates to the formal proceedings and materials associated with a shareholder meeting, specifically the notice and purpose of the meeting, which aligns best with the 'AGM Information' category, even though it is an EGM rather than a standard AGM. Since the definition for AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)', and this is the primary announcement calling for a general meeting, AGM-R is the most appropriate fit among the provided codes.
2023-08-14 English
6-K
Regulatory Filings
2023-08-09 English
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan
Regulatory Filings Classification · 99% confidence The document is a press release written in Dutch announcing a corporate event: the treatment of the first patient in a Phase III clinical trial for the drug leniolisib in Japan for APDS. It contains key financial/corporate communication elements such as a date (August 9, 2023), company name (Pharming Group N.V.), quotes from executives and doctors, details about the clinical trial, regulatory context (FDA approval, PMDA filing intent, Orphan Drug status in Japan), and standard forward-looking statements and contact information. This format is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it focuses on a specific operational/clinical milestone rather than summarizing overall financial results (which would be ER) or providing a detailed management discussion (MDA), and it is not a transcript (CT) or a formal regulatory filing like a 10-K, it best fits the category for initial announcements of key operational/clinical progress. Given the options, 'Earnings Release' (ER) is often used broadly for significant periodic announcements, but 'Regulatory Filings' (RNS) is the fallback. However, this is a proactive press release about a clinical milestone, which often accompanies or precedes an ER, but is not the ER itself. Since it is a specific, non-financial operational update, and not a short announcement pointing to a larger document, it is most closely aligned with a general corporate update. In the context of financial reporting databases, press releases detailing clinical trial progress are often categorized under the closest relevant category or as a general regulatory announcement. Given the options, and recognizing this is a major operational update, it is not a standard ER, AR, or CT. It is a specific announcement of a clinical event. If a specific 'Clinical Trial Update' category existed, it would fit there. Lacking that, and since it is a formal announcement of a significant event, it falls under the general regulatory/corporate announcement category, RNS, or potentially ER if the database uses ER broadly for period updates. Given the content is purely clinical/operational progress, RNS (Regulatory Filings/General Announcement) is the most appropriate catch-all for non-standard, yet important, corporate news that isn't a formal financial report or proxy material.
2023-08-09 Dutch
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan
Regulatory Filings Classification · 100% confidence The document is a press release dated August 9, 2023, announcing that Pharming has enrolled the first patient in a Phase III clinical trial for leniolisib in Japan. It details the trial design, mentions regulatory interactions (PMDA, FDA approval, Orphan Drug Designation from MHLW), and provides background on the disease (APDS) and the drug (Joenja®). This type of announcement, focusing on clinical trial progress and regulatory milestones, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a formal announcement of a significant business/clinical event rather than a full financial report (10-K, IR) or a transcript (CT), and it is not specifically about management changes (MANG), director trades (DIRS), or dividends (DIV), the most appropriate classification is Earnings Release (ER), as these press releases often accompany or precede quarterly financial reporting periods, or are used to disseminate material clinical progress updates to the market. Given the context of a major clinical trial update, ER is the best fit among the provided options for a material corporate announcement.
2023-08-09 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.